Comparison of mitotic index, in vitro bromodeoxyuridine labeling, and mib-1 assays to quantitate proliferation in breast cancer

Journal of Clinical Oncology

Volumn 17, Issue 2, 1999, Pages 470-477

  Thor, Ann D ^a   Liu, Shuqing ^a   Moore II, Dan H ^a   Edgerton, Susan M ^a  

^a CA

Author keywords

[No Author keywords available]

Indexed keywords

BROXURIDINE; KI 67 ANTIGEN;

ADULT; AGED; ANTIBODY LABELING; ARTICLE; BREAST CANCER; CANCER GRADING; CANCER RECURRENCE; CANCER SURVIVAL; CELL PROLIFERATION; CHEMICAL LABELING; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MITOSIS INDEX; PRIORITY JOURNAL; PROGNOSIS; QUANTITATIVE HISTOCHEMISTRY; TUMOR VOLUME;

EID: 0033015048     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/jco.1999.17.2.470     Document Type: Article

References (43)

1. Parker SL, Tong T, Bolden S, et al: Cancer statistics, 1996. CA Cancer J Clin 46:5-27, 1996
2. Sahin AA, Ro J, Ro JY, et al: Ki-67 immunostaining in node-negative stage I/II breast carcinoma. Cancer 68:549-557, 1991
3. Elston CW, Ellis IO: Pathological prognostic factors in breast cancer: I. The value of histological grade in breast cancer: Experience from a large study with long term follow-up. Histopathology 19:403-410, 1991
4. Thor AD, Edgerton SM: Cellular markers of proliferation and ongogenes, in Colvin RB, Bhan AK, McCluskey RT (eds): Diagnostic Immunopathology (ed 2). New York, NY, Raven Press, pp 669-684, 1995
5. Johnson HA, Bond VP: A method of labeling tissues with tritiated thymidine in vitro and its use in comparing rate of cellular proliferation in duct epithelium, fibroadenoma and carcinoma of the human breast. Cancer 14:639-650, 1961
6. Silvestrini R, Daidine MG, Gasparini G: Cell kinetics as a prognostic marker in node-negative breast cancer. Cancer 56:1982-1987, 1985
7. Meyer SJ, Province M: Proliferative index of breast carcinoma by thymidine labeling: Prognostic power independent of stage, estrogen and progesterone receptors. Breast Cancer Res Treat 12:191-204, 1988
8. Tubiana M, Pejovic MH, Koscielny S, et al: Growth rate, kinetics of tumor cell proliferation and long term outcome in human breast cancer. Int J Cancer 44:17-22, 1989
9. Courdi A, Dahan E, Gioanni J, et al: Factors affecting relapse in node-negative breast cancer: A multivariate analysis including the labeling index. Eur J Cancer Clin Oncol 25:351-356, 1989
10. Cooke TG, Stanton PD, Winstanley J, et al: Long-term prognostic significance of thymidine labeling index in breast cancer. Eur J Cancer 28:424-426, 1992
11. Silvestrini R: Cell kinetics: Prognostic and therapeutic implications in human tumours. Cell Prolif 27:579-596, 1994
12. 3H-Thymidine labelling index. Int J Cancer 74:122-127, 1997
13. Gratzner HG: Monoclonal antibody to 5-bromo-and-5-deoxyuridine: A new reagent for detection of DNA replication. Science 218:474-476, 1982
14. Gundez N: The use of FITC-conjugated monoclonal antibodies for determination of s-phase cells with fluorescence microscopy. Cytometry 6:597-601, 1985
15. Meyer JS, Koehm SL, Hughes JM, et al: Bromodeoxyuridine labeling for S-phase measurement in breast carcinoma. Cancer 71:3531-3540, 1993
16. Sasaki K, Matsumura K, Tsuji T, et al: Relationship between labeling indices of Ki-67 and BrdUrd in human malignant tumors. Cancer 62:989-993, 1988
17. Moriki T, Takahashi T, Kataoka H, et al: Proliferation marker MIB-1 correlates well with proliferative activity evaluated by BrdU in breast cancer: An immunohistochemical study including correlation with PCNA, p53, c-erbB-2 and estrogen receptor status. Pathol Int 46:953-961, 1996
18. Lloveras B, Garin-Chesa P, Myc A, et al: In vitro bromodeoxyuridine labeling of malignant neoplasms: A comparative study with flow cytometry cell-cycle analysis. Am J Clin Pathol 101:703-707, 1994
19. Stanton PD, Cooke TG, Forster G, et al: Cell kinetics in vivo of human breast cancer. Br J Surg 83:98-102, 1996
20. Gerdes J, Schwap U, Lemke H, et al: Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer 31:13-20, 1983
21. Gerdes J, Lemke H, Baisch H, et al: Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the mouse monoclonal antibody Ki-67. J Immunol 133:1710-1715, 1984
22. Gerdes J, Li L, Schlueter C, et al: Immunobiochemical and molecular biologic characterization of the cell proliferation-associated nuclear antigen that is defined by monoclonal antibody Ki-67. Am J Pathol 138:867-873, 1991
23. Bouzubar N, Walker KJ, Griffiths K, et al: Ki-67 immunostaining in primary breast cancer: Pathological and clinical associations. Br J Cancer 59:943-947, 1989
24. Wintzer H-O, Zipfel I, Shulte-Mönting J, et al: Ki-67 immunostaining in human breast tumors and its relationship to prognosis. Cancer 67:421-428, 1991
25. Stumpp J, Dietl J, Simon W, et al: Growth fraction in breast carcinoma determined by Ki-67 immunostaining: Correlation with pathological and clinical variables. Gynecol Obstet Invest 33:47-50, 1992
26. Lee AK, Loda M, Mackarem G, et al: Lymph node negative invasive breast carcinoma 1 centimeter or less in size (T1a,bN0M0): Clinicopathologic features and outcome. Cancer 79:761-771, 1997
27. Querzoli P, Albonico G, Ferretti S, et al: MIB-1 proliverative activity in invasive breast cancer measured by image analysis. J Clin Pathol 49:926-930, 1996
28. Arber JM, Riggs MW, Arber DA: Correlation among MIB-1, paraffin section proliferation index, and recurrence in low stage breast carcinoma. Appl Immunohistochem 5:117-124, 1997
29. Key G, Becker MHG, Baron B, et al: New Ki-67 equivalent murine monoclonal antibodies (MIB1-3) generated against bacterially expressed parts of the Ki-67 cDNA containing three 62 base pair repetitive elements encoding for the Ki-67 epitope. Lab Invest 68:629-636, 1993
30. Cattoretti G, Bechke MHG, Key G, et al: Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB-1 and MIB-3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections. J Pathol 168:357-363, 1992
31. Kelleher L, Jagee HM, Dervan PA: Evaluation of cell-proliferation antibodies reactive in paraffin sections. Appl Immunohistochem 2:164-170, 1994
32. Markiewski M, Domagala W: Immunohistochemical assessment of proliferation rate of breast carcinoma cells using Ki-67, MIB-1 and anti-PCNA monoclonal antibodies. Pol J Pathol 47:189-194, 1996
33. Beck T, Weller EE, Weikel W, et al: Usefulness of immunohistochemical staining for p53 in the prognosis of breast carcinomas: Correlations with established prognosis parameters and with the proliferation marker, MIB-1. Gynecol Oncol 57:94-104, 1995
34. Pinder SE, Wencyk P, Sibbering DM, et al: Assessment of the new proliferation marker MIB1 in breast carcinoma using image analysis: Associations with other prognostic factors and survival. Br J Cancer 71:146-149, 1995
35. Pietilainen T, Lipponen P, Aaltomaa S, et al: The important prognostic value of Ki-67 expression as determined by image analysis in breast cancer. J Cancer Res Clin Oncol 122:687-692, 1996
36. Lloveras B, Edgerton S, Thor AD: Evaluation of in vitro bromodeoxyuridine labelling of breast carcinomas with the use of a commercial kit. Am J Clin Pathol 95:41-47, 1991
37. Clark GM: Prognostic and predictive factors, in Harris JR, Lippman ME, Morrow M, Hellman S (eds): Diseases of the Breast. Philadelphia, PA, Lippincott-Raven, 1996, p 466
38. Hartman WH, Uzello L, Sobin LH, et al (eds): Histological Typing of Breast Tumors (ed 2). Geneva, Switzerland, World Health Organization, pp 15-25, 1981
39. Koerner FC, Goldberg DE, Edgerton SM, et al: pS2 protein and steroid hormone receptors in invasive breast carcinomas. Int J Cancer 52:183-88, 1992
40. Cox DR: Regression models and life-tables. J Royal Stat Soc Ser B 34:187-202, 1972
41. Therneau TM, Grambsch PM, Fleming TR: Martingale-based residuals for survival models. Biometrika 77:147-160, 1990
42. Statistical Sciences. S-PLUS Version 3.3 Supplement. Seattle, WA, StatSci, a division of MathSoft, Inc, 1995
43. Collett D: Modelling Survival Data in Medical Research. London, England, Chapman & Hall, 1994